Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathy

dc.contributor.authorKazan, D. E.
dc.contributor.authorKazan, S.
dc.date.accessioned2023-04-27T12:46:50Z
dc.date.available2023-04-27T12:46:50Z
dc.date.issued2023en_US
dc.departmentAFSÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjective: We aimed to investigate the prognostic values of systemic immune inflammation index and pan-immune inflammation value in patients with idiopathic low and moderate risk membranous nephropathy. Patients and methods: All membranous nephropathy patients diagnosed in the nephrology clinic between January 2015 and January 2022 were reviewed retrospectively. Patients with idiopathic membranous nephropathy were included. The patients were divided into two groups; the complete remission group: whose proteinuria decreased below 0.3 g/day and serum albumin level above 3.5 g/dL after 6 months of conservative treatment, and the non-remission group: all other patients. Groups were compared in terms of systemic immune inflammation index and pan-immune inflammation value. Results: Patients in the non-remission group had significantly higher systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) than patients in the complete remission group (p<0.05). An SII of 1,056.2 was found to have 63.6% sensitivity and 100% specificity in predicting non-remission, and a PIV of 447.4 was found to have 100% sensitivity and 70.6% specificity in predicting non-remission. Conclusions: SII and PIV are reliable markers for predicting non-remission in patients with low and moderate risk idiopathic MN.en_US
dc.identifier.citationKazan, D. E., & Kazan, S. (2023). Systemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathy. Eur Rev Med Pharmacol Sci, 27(2), 642-648.en_US
dc.identifier.doi10.26355/eurrev_202301_31065
dc.identifier.endpage648en_US
dc.identifier.issn2284-0729
dc.identifier.issue2en_US
dc.identifier.pmid36734708
dc.identifier.scopus2-s2.0-85147313496
dc.identifier.scopusqualityQ2
dc.identifier.startpage642en_US
dc.identifier.urihttps://dx.doi.org/10.26355/eurrev_202301_31065.
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1488
dc.identifier.volume27en_US
dc.identifier.wosWOS:000933582100010
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKazan, D. E.
dc.institutionauthorKazan, S.
dc.language.isoen
dc.publisherVerducien_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInflammationen_US
dc.subjectMembranous Nephropathyen_US
dc.subjectPan-Immune Inflammation Valueen_US
dc.subjectRemissionen_US
dc.subjectSystemic Immune Inflammation Indexen_US
dc.titleSystemic immune inflammation index and pan-immune inflammation value as prognostic markers in patients with idiopathic low and moderate risk membranous nephropathyen_US
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Kazan.D.E.2023.pdf
Boyut:
595.81 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: